Piramal Pharma Gears Up for Q3 Reveal on 28th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results 

Piramal Pharma’s Q3 results FY26 are scheduled to be announced on 28th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Piramal Pharma Q3 Results 2026 Preview

• Piramal Pharma’s revenue is expected to be in the range of ₹2,204.22 crore, a 30% YoY decrease. 
• Profit After Tax, or PAT, is projected to fall by 83.71% YoY. 
• Piramal Pharma’s EBITDA is expected to fall to ₹140.93 crore. 
• Net profit is ₹3.68 crore, a fall 83.71% YoY 

Piramal Pharma Share Performance 

• Over the past six months, Piramal Pharma’s share price has fallen by 26.20% to ₹150.83.
• Moreover, over the past year, the stock has decreased by 32.63%.
• Despite this weak short-term performance, Piramal Pharma’s stock has delivered a financially sound 9.91% return over the past 5 years.
• As of 27th January 2026, the stock traded at ₹150.84 per share.

Key Factors to Watch for Piramal Pharma Q3 Results FY26 

• Revenue growth & segment performance – Trend in overall sales and how key businesses like CDMO (Contract Development & Manufacturing), Complex Hospital Generics (CHG), and India Consumer Healthcare are performing.
• Profitability & margins – Net profit or loss, EBITDA and operating margin trends reflecting cost control, pricing and business mix.
• CDMO order flows & global demand – Strength and stability of order inflows, especially in US/Europe markets, amid macro uncertainties and inventory destocking impacts.
• Regulatory & quality developments – USFDA inspection outcomes and compliance status that affect export market access and customer confidence.
• Cost & capacity dynamics – Raw material costs, R&D spend and capacity utilisation at manufacturing facilities influencing margins and future growth.

Final Thoughts

Piramal Pharma will announce its Q3 FY26 results on 28th January 2026. Analysts expect 1.67% YoY revenue growth, a 83.71% fall in PAT, and a 5.66% fall in EBITDA. Piramal Pharma focuses on: driving revenue growth through its CDMO and hospital generics businesses while maintaining margins and regulatory compliance.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

Top 10 Penny Stocks in India | Penny Stocks to Buy in 2026

Best Stocks to Buy Today: Explore Best Stocks With Expected Trends

Milky Mist Dairy Foods IPO Details: Everything You Should Know about 

Karbonsteel Engineering IPO GMP & Review: Should You Apply or Avoid?

Taurian MPS IPO GMP & Review: Should You Apply or Avoid?

Shringar House of Mangalsutra IPO GMP & Review: Apply or Avoid?

Dev Piramal Pharmaelerator IPO GMP & Review: Apply or Avoid?

Vigor Plast India IPO Listing Preview: What to Expect Now?

Krupalu Metals IPO GMP: Day 3 IPO Live Updates